Last updated on: 06/07/2020
Name of organisation
1) Department/Research groupMedicines Monitoring Unit
2) Organisation/affiliationUniversity of Dundee
Short Name in the inventoryMEMO
Administrative Contact
Title Mrs
Last name Mitchell
First name Lyn
Address line 1Medicines Monitoring Unit/Hypertension Research Centre
Address line 2Ninewells Hospital & Medical School
Address line 3Level 7
CityDundee
PostcodeDD1 9SY
CountryUnited Kingdom
Phone number (incl. country code)441382383119
Alternative phone number441382383232
Fax number (incl. country code)441382643204
Scientific Contact
Title Professor
Last name MacDonald
First name Thomas
Address line 1Medicines Monitoring Unit/Hypertension Research Centre
Address line 2Ninewells Hospital & Medical School
Address line 3Level 7
CityDundee
PostcodeDD1 9 SY
CountryUnited Kingdom
Phone number (incl. country code)441382383119
Alternative phone number441382383232
Fax number (incl. country code)441382643204
2. Description
Medicines Monitoring Unit (MEMO), Ninewells Hospital and Medical School
Undertakes research into the safe, effective and cost-effective use of medicines and devices as well as helping to improve the understanding of disease using anonymised healthcare data.
3. Category
University based
Charity or non-profit organisation
4. Available resources
In houseVia Contacts/Network
5. Therapeutic/disease areas of research in drug safety/risk-benefit performed in the past 5 years
Cardiovascular diseases
Disorders of the central nervous system
Endocrine disorders
Gastrointestinal tract
Geriatrics
Gynaecology
Immunological products and vaccines
Immunosuppression
Infectious diseases
Liver disease
Malignant disease
Musculoskeletal and joint diseases
Osteoporosis
Poisoning/Overdose
Pregnancy
Psychiatry
Renal impairment
Respiratory diseases
Skin disorders
Urinary tract disorders
6. Design of drug safety/risk-benefit studies published in the past 5 years
Cohort Study
Case Control Study
Drug Utilisation
Interventional Clinical Trial
Meta-Analysis
7. Experience in collecting data directly from individual patients/respondents
Number of Studies
Greater than 5
Number of patients/respondents involved in the study(ies)
Greater than 15000
8. Access to data collection resources
Capacity to conduct face-to-face interviews
Yes
In a clinic
Yes
In the community
Yes
Electronic data capture systems
Yes
System used:
Secure Website
Interactive voice response systems
Yes
Call centre
Yes
9. Experience in secondary research and meta-analysis
Yes
10. Work with existing data resources in the past 3 years
Name of data resourceNo. of studies
MEMO50
CPRS5
11. Registries established by centre
Disease RegistryMS,OA
Other Randomised Trial Databases
12. Experience in collaboration in a study team
Principal Investigator
Collaborating Investigator
13. Current involvement in research networks
Other networks:
Network nameNationalInternationalLink to webpage
14. Interest in research opportunities which are funded
By pharmaceutical companies
By charities
By government
By research councils
By EU funding schemes
15. Interest in contract research only if free to publish results
Yes
16. Selected publications of the last 5 calendar years
ReferenceLink to web-publication
MacDonald TM, Hawkey CJ, Ford I, McMurray JJV, Scheiman JM, Hallas J, Findlay E, Grobbee DE, Hobbs FDR, Ralston SH, Reid DM, Walters MR, Webster J, Ruschitzka F, Ritchie LD, Perez-Gutthann S, Connolly E, Greenlaw N, Wilson A, Wei L, Mackenzie IS. Randomised trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: The Standard care versus Celecoxib Outcome Trial (SCOT).
European Heart Journal 2017;38:1843-1850
Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ; British Hypertension Society's PATHWAY Studies Group.Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Lancet. 2015;387:1373-4.
Rogers A, Morrison I, Rorie DA, Mackenzie IS, MacDonald TM. Protocol for assessment of sleep quality and duration in the Treatment In Morning versus Evening (TIME) study: a randomised controlled trial using online patient-reported outcome measures. BMJ Open. 2018 Jun 7;8(6):e021890.
Brown MJ, Williams B, Morant SV, Webb DJ, Caulfield MJ, Cruickshank JK, Ford I, McInnes G, Sever P, Salsbury J, Mackenzie IS, Padmanabhan S, MacDonald TM; British Hypertension Society's Prevention; Treatment of Hypertension with Algorithm-based Therapy (PATHWAY) Studies Group. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial.
Lancet Diabetes Endocrinol. 2016;4:136-47.
Mackenzie IS, Morant SV, Wei L, Thompson AM, MacDonald TM. Spironolactone use and risk of incident cancers: a retrospective, matched cohort study.
Br J Clin Pharmacol. 2017;83:653-663
